Pfizer Inc. (NYSE:PFE) Shares Sold by FARMERS & MERCHANTS TRUST Co OF LONG BEACH

FARMERS & MERCHANTS TRUST Co OF LONG BEACH trimmed its position in Pfizer Inc. (NYSE:PFE) by 24.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,811 shares of the biopharmaceutical company’s stock after selling 9,904 shares during the period. FARMERS & MERCHANTS TRUST Co OF LONG BEACH’s holdings in Pfizer were worth $781,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Pfizer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock worth $13,756,738,000 after purchasing an additional 2,285,276 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Pfizer by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after buying an additional 2,923,537 shares in the last quarter. Norges Bank bought a new position in shares of Pfizer in the fourth quarter valued at $2,328,986,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 1.3%

Pfizer stock opened at $24.51 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $139.35 billion, a price-to-earnings ratio of 17.38, a PEG ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company’s fifty day moving average price is $23.06 and its two-hundred day moving average price is $24.95.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.82 earnings per share. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.02%. The ex-dividend date was Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

Analyst Ratings Changes

Several research firms have issued reports on PFE. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group increased their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.